Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imvotamab in Severe Systemic Lupus Erythematosus
NCT06041568Phase 1Terminated
- Sponsor
- IGM Biosciences
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of imvotamab in systemic lupus erythematosus (SLE), sponsored by IGM Biosciences. Primary endpoint: Safety and tolerability of imvotamab. Started Aug 2023; status: terminated.
02
Drugs
imvotamab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06041568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041568.